Status:
COMPLETED
Endothelin Receptor Antagonism in Proteinuric Nephropathy
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
British Heart Foundation
Conditions:
Chronic Kidney Disease
Proteinuria
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (pr...
Detailed Description
Response to ETA Receptor Antagonism/Nifedipine/Placebo Prior to the study visit subjects will be asked to refrain from alcohol for 24 hours. Tea and coffee will not be permitted for at least 12 hours ...
Eligibility Criteria
Inclusion
- Male or female
- Age 18-70
- Body mass index \<35
- Blood pressure \<160/110 mmHg
- CKD stage 2-5 as per the K/DOQI classification
- Proteinuria in one of the following categories: 0.3-1.5, \>1.5-3.0, and \>3.0-6.0 g/24hrs
- Normal serum albumin
Exclusion
- Subject is below the age of legal consent, or is mentally or legally incapacitated
- History of multiple and/or severe allergic reactions to drugs (including study drugs), or food
- The subject has donated blood (450 ml) within the last 4 weeks
- Past or present drug or alcohol abuse including intravenous drug abuse at any time
- Participation in another clinical trial within 1 month
- Considered to be at high risk of HIV or hepatitis B
- Pregnant
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00722215
Start Date
May 1 2006
End Date
December 1 2007
Last Update
July 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Centre, Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU